Dr. Lal PathLabs has introduced India’s first Comprehensive Complement Testing Laboratory, offering a range of tests available for the first time in the country. A 2024 study indicated a 30% increase in autoimmune disorders following the pandemic, with individuals aged 31-45 showing the most significant increase. This advanced facility will enable faster, more accurate diagnosis of autoimmune, kidney, and infection-related conditions.
Advanced Autoimmune Diagnostics
Dr. Lal PathLabs (DLPL) has launched India’s inaugural Comprehensive Complement Testing Laboratory. The lab aims to improve diagnostics for autoimmune conditions with advanced testing capabilities.
Key Benefits of the New Lab
This new facility enables doctors to diagnose autoimmune, kidney, and recurrent infection-related conditions more effectively. The complement testing helps uncover the underlying immune disturbance and provides clarity for earlier, more accurate diagnosis and treatment.
Complement System Explained
The complement system involves blood proteins that fight infections and protect organs. If weak, it can lead to repeated infections; if overactive, it may attack healthy tissues, leading to conditions such as lupus, kidney diseases, vasculitis, rheumatoid arthritis, and sepsis.
Statements from Leadership
Dr. Vandana Lal, Executive Director, Dr. Lal PathLabs, stated that the new lab will enable earlier and more precise insights into immune-mediated disease, bridging the gap between research and routine clinical care.
Mr. Shankha Banerjee, CEO, Dr. Lal PathLabs, mentioned that this marks a significant step toward faster diagnosis, better treatment decisions, and improved outcomes for those living with autoimmune and kidney diseases.
Laboratory Capabilities
The Complement Laboratory has state-of-the-art immunoturbidimetric and ELISA platforms and adheres to CAP and NABL accreditation standards. The goal is to offer greater clarity and control over disease management, leading to reduced healthcare costs and improved quality of life.
Source: BSE
